New York Senate Bill S00438

New York 2025-2026 Regular Session

• Introduced: 1/8/25
• Refer: 1/8/25
• Engrossed: 2/25/25
• Refer: 2/25/25
• Refer: 1/7/26
• Engrossed: 2/24/26
• Refer: 2/24/26
• Engrossed: 3/24/26
• Refer: 3/24/26

Caption

Establishes the prescription drug supply chain transparency act; requires pharmacy services administrative organizations, pharmacy switch companies and rebate aggregators to register with the insurance department and to provide certain disclosures relating to the ownership and activities of such entities; relates to deposits into the pharmacy benefit manager regulatory fund.

Impact

The implications of this legislation are significant, as it introduces a framework for regulatory oversight of pharmacy benefit managers and their affiliates in New York. This new measure is designed to ensure that the operations of these entities are transparent and accountable to the regulatory authorities, thereby contributing to consumer protection. The bill also establishes a regulatory fund to collect penalties and fees from these entities, thus fostering a fiscal mechanism aimed to support the enforcement of the new regulations. It will aid in monitoring compliance and protect the interests of consumers within the state's healthcare ecosystem.

Summary

S00438, known as the Prescription Drug Supply Chain Transparency Act, seeks to enhance transparency within the pharmaceutical supply chain by imposing registration and reporting requirements on pharmacy services administrative organizations, pharmacy switch companies, and rebate aggregators. The bill necessitates these entities to register with the Department of Insurance and provide detailed disclosures concerning their ownership and operational activities. By mandating such transparency, the legislation aims to promote fair practices and reduce potential conflicts of interest that could arise within the supply chain marketing practices.

Contention

Discussion surrounding S00438 may reflect notable points of contention particularly concerning the balance between regulation and operational flexibility for providers in the pharmaceutical industry. Opponents may argue that the additional regulatory burden could potentially stifle innovation and limit the access of smaller entities to operate within the state. On the other hand, advocates for the bill highlight the necessity of this oversight to combat pharmaceutical pricing secrecy and ensure that the supply chain is not exploited at the expense of consumers relying on medications. Overall, the debate may center around the efficacy of such regulations in truly achieving transparency versus the unintended consequences on market operations.